Corsini EM, Datar SS, Mitchell KG, Zhou N, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG , Vaporciyan AA, Walsh GL, Blackmon SH, Loree JM, Morris VK, Antonoff MB
In lab tests, people taking semaglutide drank less alcohol and said they felt fewer cravings than the people who were given a placebo
The FDA flagged marketing claims suggesting that compounded GLP-1s shared the same safety and efficacy profiles as their branded counterparts, noting that such labeling can mislead consumers and violate the Food, Drug, and Cosmetic Act
The only formal clinical dose in the human record is the postoperative-ileus trial, which used 0.03 mg/kg intravenously twice daily for up to seven days